Drwy gynllun mynediad cleifion rhwng GIG Cymru a'r cynhyrchwr, Bristol-Myers Squibb, bydd y cyffur ar gael i drin rhai pobl sy'n dioddef o ganser yr ysgyfaint celloedd bach datblygedig, hyd yn oed os ydynt wedi cael triniaeth cemotherapi.
A patient access scheme between NHS Wales and the manufacturer, Bristol-Myers Squibb, means that it will be available to treat some people with advanced non-small cell lung cancer, if they have already been treated with chemotherapy.